• DOI:10.1159/000055400
Corpus ID: 24924864

First-Line Herceptin® Monotherapy in Metastatic Breast Cancer

@article{Vogel2001FirstLineHM,
  title={First-Line Herceptin® Monotherapy in Metastatic Breast Cancer},
  author={C. Vogel and M. Cobleigh and D. Tripathy and J. Gutheil and L. N. Harris and L. Fehrenbacher and D. Slamon and M. Murphy and W. Novotny and M. Burchmore and S. Shak and S. Stewart},
  journal={Oncology},
  year={2001},
  volume={61},
  pages={37 - 42}
}

C. Vogel, M. Cobleigh, +9 authors S. Stewart

Published 2001

Medicine

Oncology

The pivotal phase II and III Herceptin® trials proved the efficacy and safety of second- or third-line single-agent Herceptin and first-line Herceptin in combination with chemotherapy, respectively. In the current trial, 114 patients were randomized to one of two dose groups of first-line Herceptin monotherapy: standard dose of 4 mg/ kg initial dose followed by 2 mg/kg intravenous (i.v.) weekly; or high dose of 8 mg/kg initial dose followed by 4 mg/kg i.v. weekly. The regimen was generally well… CONTINUE READING

View on PubMed

doi.org

Save to Library

Create Alert

Cite

Launch Research Feed